Peter Villiger - ATyr Pharma Vice Development
Executive
Peter Villiger is Vice Development of ATyr Pharma
| Phone | 858 731 8389 |
| Web | https://www.atyrpharma.com |
ATyr Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2937) % which means that it has lost $0.2937 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5561) %, meaning that it created substantial loss on money invested by shareholders. ATyr Pharma's management efficiency ratios could be used to measure how well ATyr Pharma manages its routine affairs as well as how well it operates its assets and liabilities.ATyr Pharma currently holds 15.1 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. ATyr Pharma has a current ratio of 9.88, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ATyr Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mark MBA | X4 Pharmaceuticals | 60 | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| MS MBA | PDS Biotechnology Corp | 58 | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Gregory Conn | PDS Biotechnology Corp | 69 | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Lars MBA | PDS Biotechnology Corp | 54 | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| JD Esq | Terns Pharmaceuticals | 55 | |
| MBA MD | X4 Pharmaceuticals | 62 | |
Management Performance
| Return On Equity | -0.56 | |||
| Return On Asset | -0.29 |
ATyr Pharma Leadership Team
Elected by the shareholders, the ATyr Pharma's board of directors comprises two types of representatives: ATyr Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ATyr. The board's role is to monitor ATyr Pharma's management team and ensure that shareholders' interests are well served. ATyr Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ATyr Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Danielle Campbell, VP Resource | ||
| Melissa Ashlock, Vice President - External Scientific Alliances and Human Genetics | ||
| MS MD, CEO President | ||
| XiangLei Yang, Founder | ||
| Ying Buechler, Executive Manufacturing | ||
| Jill Broadfoot, Chief Officer | ||
| David King, Senior Vice President - Research | ||
| Ashlee Dunston, Director Communications | ||
| Peter Villiger, Vice Development | ||
| Leslie Nangle, Vice Research | ||
| Nancy Krueger, General Secretary |
ATyr Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ATyr Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (70.79) % | |||
| Current Valuation | 55.05 M | |||
| Shares Outstanding | 69.01 M | |||
| Shares Owned By Insiders | 2.61 % | |||
| Shares Owned By Institutions | 61.69 % | |||
| Number Of Shares Shorted | 343.41 K | |||
| Price To Earning | (2.19) X | |||
| Price To Book | 1.30 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in ATyr Stock
If you are still planning to invest in ATyr Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ATyr Pharma's history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |